Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Inclusion criteria

Patients must have the following:

• Stage III or IV HIV infection.
• Provide informed consent.

Exclusion criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Kaposi's sarcoma lesions in the proposed treatment sites.
• Liable to require radiation or chemotherapy during the course of the study.
• Not likely to survive the length of the study.
• Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:
• holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

Concurrent Medication:

Excluded:

• Other Immunomodulators.

Concurrent Treatment:

Excluded:

• Radiation.

Patients with the following are excluded:

• Kaposi's sarcoma lesions in the proposed treatment sites.
• Liable to require radiation or chemotherapy during the course of the study.
• Not likely to survive the length of the study.
• Obvious ultra-violet-irradiated skin damage in the treatment areas.
• Allergy to lidocaine.

Prior Medication:

Excluded:

• Prior DNCB therapy.